Section Arrow
RLYB.NASDAQ
- Rallybio Corporation
Quotes are at least 15-min delayed:2026/04/14 19:25 EDT
After Hours
Last
 8.25
0 (0.00%)
Bid
8.2
Ask
9.2
High 8.25 
Low 8.25 
Volume
Regular Hours (Closed)
Last
 8.25
-0.05 (-0.60%)
Day High 
8.485 
Prev. Close
8.3 
1-M High
9.945 
Volume 
39.61K 
Bid
8.2
Ask
9.2
Day Low
8.215 
Open
8.32 
1-M Low
7.9 
Market Cap 
43.90M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 8.32 
20-SMA 8.63 
50-SMA 7.59 
52-W High 11.49 
52-W Low 1.96 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.59/-0.97
Enterprise Value
43.99M
Balance Sheet
Book Value Per Share
10.96
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
858.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HOTHHoth Therapeutics0.6459+0.134+26.18%-- 
After Hours 0.65 +0.0041 +0.63%
ALLOAllogene Therapeutics2.28-0.78-25.49%-- 
After Hours 2.19 -0.09 -3.95%
VRAXVirax Biolabs Group Limited0.148-0.0184-11.06%-- 
After Hours 0.1384 -0.0096 -6.49%
CMNDClearmind Medicine Inc.0.91-0.52-36.36%-- 
After Hours 0.8558 -0.0542 -5.96%
REPLReplimune Group1.95+0.25+14.71%-- 
After Hours 1.9001 -0.0499 -2.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rallybio Corp is a clinical-stage biotechnology company engaged in the development of therapeutic candidates for severe and rare diseases. It focuses on the treatment of conditions related to complement dysregulation and hematologic disorders. The company's flagship program, RLYB116, is a C5 inhibitor being evaluated for potential use in diseases associated with complement dysregulation, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody candidate under investigation for the treatment of iron overload disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.